KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vir Biotechnology (VIR) EPS (Weighted Average and Diluted) (2020 - 2025)

Vir Biotechnology (VIR) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.3 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 60.53% to -$0.3 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.15 through Dec 2025, up 17.54% year-over-year, with the annual reading at -$3.16 for FY2025, 17.49% up from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.3 in Q4 2025 for Vir Biotechnology, up from -$1.17 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $3.94 in Q4 2021 to a low of -$1.56 in Q3 2024.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.19 across 5 years, with a median of -$0.78 in 2024.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 563.53% in 2021 and later crashed 226.09% in 2022.
  • Year by year, EPS (Weighted Average and Diluted) stood at $3.94 in 2021, then plummeted by 119.04% to -$0.75 in 2022, then decreased by 14.67% to -$0.86 in 2023, then grew by 11.63% to -$0.76 in 2024, then skyrocketed by 60.53% to -$0.3 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for VIR at -$0.3 in Q4 2025, -$1.17 in Q3 2025, and -$0.8 in Q2 2025.